CLVS News and Press, Clovis Oncology Inc. From 11/14/22

Summary Shares of early clinical-stage biotech Tango Therapeutics, Inc. are down ~50% since going public in August 2021 – primarily victimized by a lack of catalysts and a tough market. However, the shares have rallied strongly over the past month. Tango Therapeutics&#x...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: rafapress / Shutterstock.com Clovis Oncology (NASDAQ: CLVS ) stock is crashing on Wednesday as investors react to news of the company running out of cash ! According to a recent filing from Clovis Onc...

Clovis Oncology ( NASDAQ: CLVS ), a biotech focused on cancer therapies, announced Wednesday warned of near-term bankruptcy and cited liquidity constraints in its latest 10-Q filing on Wednesday. Clovis ( CLVS ) shares are currently on hold for trading. Clovis, which d...

Summary AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Over the past three quarters, a slew of AstraZeneca's medicines have received regulatory approvals from the US, Europe, Japan, and China, thereby maintainin...

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and research is constantly advancing. Pancreatic cancer is 12 ...

Summary Clovis Oncology continues to report positive clinical data from Rubraca and FAP-2286. I believe these updates make Clovis a prime acquisition target. I review some of the company’s recent updates. I discuss the downside risks of adding a buyout aspect to my bull...

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, “TRITON3: A Phase 3 Study of Rucaparib vs. Physicianȁ...

Clovis Oncology ( NASDAQ: CLVS ) on Monday reported updated phase 1 data from the a phase 1/2 trial of radiotherapy candidate FAP-2286 labeled with lutetium-177 ( 177 Lu-FAP-2286) to treat tumors. The company noted that FAP-2286 targets fibroblast activatio...

Updated LuMIERE Phase 1 data demonstrated a manageable safety profile with some preliminary evidence of anti-tumor activity Eleven patients treated to date with 177 Lu-FAP-2286 up to 7.4 GBq/dose No serious adverse events, treatment discontinuations, or deaths re...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Faizal Ramli/Shutterstock.com Xperi (NASDAQ: XPER ) stock is falling on Friday after the company completed a spinoff of itself from its IP licensing business. That spinoff has Xperi separating itself...